CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Unipharm AD is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Unipharm AD
ul. Trayko Stanoev No 3
Phone: +359 29700305p:+359 29700305 SOFIA, 1797  Bulgaria Fax: +359 29712086f:+359 29712086
This company is no longer actively traded on any major stock exchange.
Business Summary
Unipharm AD (Unipharm JSC) is a Bulgaria-based company which specializes in the preparation, development, production, packaging and distribution of medicines, as well as in the scientific research and tests in the field of the medicines production. Through its tablet and sales departments, microbiological laboratory and warehouses for raw materials and finished products, the Company manufactures and distributes two major product lines: Liquid drugs, including concentrates for haemodialysis, eye-drops, nasal drops and gels, and Solid drugs, including antithrombotic agents, antiasthmatic agents, antineoplastics, antispasmodics and non-steroidal anti-inflammatory, antirheumatic drugs and supplementary food. Unipharm AD is active in Bulgaria and abroad in Poland, the Baltic States, the Russian Federation, Ukraine and Georgia, among others. As of December 31, 2011, the Company’s major shareholder was Sopharma AD with a stake of 49.99%.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201812/31/2017Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board Ognian I.Donev 60 1/1/1998 1/1/1998
Chairman of the Management Board, Chief Executive Officer Ognyan K.Palaveev 69
Vice Chairman of the Management Board, Deputy Technical Director Dimitar D.Chipanov 61
5 additional Officers and Directors records available in full report.

General Information
Stock Exchange: BUL
Fax Number: +359 29712086


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023